Deep-Biotech: an umbrella that hosts our mission tracks
Explore new territories. R&D towards new applied research. Develop new products and outcomes to provide services to industries and end users.

Bio-Explore
[Track-1]
Explore and develop new interdisciplinary R&D concepts, tied to applied use cases, covering market needs and gaps. Build new partnerships, consortiums, novel MVPs, products and services via Tracks 2, 3. Exploit outcomes in business development opportunities.

R&D, Products
[Track-2]
Basic and applied research development towards novel MVPs/PoC, products within state-of-the art science and technology in computational biology and deep-learning.
Outcomes: "DeNViS", Deep Neural Virtual Screening for drug discovery.

Services, R&D Consulting
[Track-3]
Develop and deliver software engineering, production-level outcomes, publications, customised studies, tailor built solutions and consulting services to pharmaceutical, biotech-like industries.
More information soon.
Pipeline: Explore, R&D, Business Exploitation

Timeline and News
-
Mar 1, 2020
First concept
High-level motivation and brainstorming led to the initial drug discovery concept; after research we decided to focus on high-throughput virtual screening via structure-based protein-ligand affinity prediction.
-
May 1, 2020
R&D Self-funded Project
Form ML-Team; +new bio-engineer hiring; ongoing R&D work; production-level engineering scale up.
-
Jul 20, 2020
JEDI Grand Challenge submission
Successful fast screening of 1B molecules; submission of ranked compounds to the JEDI Grand challenge international effort against covid-19 related proteins.
-
Oct 1, 2020
R&D, Networking
- Virtual screening R&D cont'd
- Initiate single cell multi-omics tracks
- Develop research project proposals and networking with pharma/biotech companies.
-
Jan 5, 2021
Bio-Explore
- Bio-Explore concept and framework formation [Dec., 2021].
- New bioinformaticians/bio-explore team [Jan., 2021].
- Project kick-off [Feb., 2021].
-
Mar 1, 2021
Positive Outcomes, +Business
- JEDI positive feedback: deeplab is within 20-top finalists; molecules are to be screened in wet lab.
- New strategic health market and business lead position.
-
May 1, 2021
Upcoming potential
- Submit Virtual screening product (DeNViS) business proposals on open funding calls (EIT, Bio-Tools) [May, 2021].
- Technical report on Virtual Screening manuscript ready for publication.
- Single-cell multi-omics 2nd cycle proposals with pharma industry [May, 2021].
- Website goes live [Jun., 2021].